Skip to main content

08-06-2021 | ASCO 2021 | Conference coverage | Video

PEACE-1 points to benefit of adding abiraterone to ADT–docetaxel in de novo mCSPC

Karim Fizazi describes results from the phase 3 PEACE-1 trial suggesting that the combination of abiraterone, androgen deprivation therapy, and docetaxel could be an option for patients with a new diagnosis of metastatic castration-sensitive prostate cancer (5:58).

Read transcript

2021 ASCO Annual Meeting coverage

Access news and expert commentary from the 2021 ASCO Annual Meeting

Image Credits